75 Myocardial fibrosis in esophageal cancer patients References [1] Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–8. https://doi.org/10.1016/S1470-2045(15)00040-6. [2] Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, et al. Clinical and Translational Radiation Oncology Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 2019;17:17–23. https://doi.org/10.1016/j. ctro.2019.04.016. [3] Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol 2015;6:516–23. https:// doi.org/10.3978/j.issn.2078-6891.2015.040. [4] Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: An analysis of the surveillance, epidemiology, and end result database. PLoS One 2016;11. https://doi.org/10.1371/journal.pone.0158916. [5] Beukema JC, van Luijk P, Widder J, Langendijk J a., Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 2015;114:85–90. https://doi. org/10.1016/j.radonc.2014.11.037. [6] Wang X, Palaskas NL, Yusuf SW, Abe J ichi, Lopez-Mattei J, Banchs J, et al. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J Thorac Oncol 2020. https:// doi.org/10.1016/j.jtho.2020.06.014. [7] Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensitymodulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:1078–85. https://doi.org/10.1016/j.ijrobp.2012.02.015. [8] Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 2013;87:487–93. https://doi.org/10.1016/j.ijrobp.2013.07.008. [9] Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743–9. https://doi.org/10.1016/S07351097(03)00759-9. [10] Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981;70:519–30. https://doi.org/10.1016/0002-9343(81)90574-X. [11] Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 2014;9:1554–60. https://doi. org/10.1097/JTO.0000000000000306. [12] Seemann I, Gabriels K, Visser NL, Hoving S, te Poele J a, Pol JF, et al. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother Oncol 2012;103:143–50. https://doi.org/10.1016/j. radonc.2011.10.011. [13] Parsai C, Ohanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:1. https://doi.org/10.1186/1532-429X-14-54. [14] Patel AR, Kramer CM. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. JACC Cardiovasc Imaging 2017;10:1180–93. https://doi. org/10.1016/j.jcmg.2017.08.005. [15] MacHann W, Beer M, Breunig M, Störk S, Angermann C, Seufert I, et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 2011;79:1117–23. https://doi.org/10.1016/j.ijrobp.2009.12.054. 5
RkJQdWJsaXNoZXIy MTk4NDMw